Table 5.
ALLY-1: SVR12 in Genotype 1 Patients with Child–Pugh A, B, or C Cirrhosis Or With HCV Genotype 1 Recurrence After Liver Transplantation Treated With Daclatasvir in Combination With Sofosbuvir and Ribavirin for 12 Weeks8
| Treatment Outcomes | Child–Pugh A, B, or C Cirrhosis (n = 45) | Post-Liver Transplant (n = 41) |
|---|---|---|
|
| ||
| SVR12 | ||
| Genotype 1 | 82% (37/45) | 95% (39/41) |
| Genotype 1a | 76% (26/34) | 97% (30/31) |
| Genotype 1b | 100% (11/11) | 90% (9/10) |
| Child–Pugh A | 91% (10/11) | – |
| Child–Pugh B | 92% (22/24) | – |
| Child–Pugh C | 50% (5/10) | – |
|
| ||
| Outcomes for patients without SVR12 | ||
| On-treatment virological failure | 2% (1/45)a | 0 |
| Relapseb | 16% (7/44) | 5% (2/41) |
HCV = hepatitis C virus; SVR12 = sustained virological response at post-treatment week 12.
a
One subject had detectable HCV RNA at end of treatment.
b
Relapse rates are calculated with a denominator of patients with HCV RNA not detected at end of treatment.